Global Manufacturing Footprint Unither Pharmaceuticals operates eight manufacturing plants across France, the US, Brazil, and China, providing extensive geographic coverage that facilitates localized supply chains and reduces delivery times, presenting opportunities to win contracts requiring regional manufacturing capabilities.

Specialized Technological Expertise The company's focus on innovative niche technologies such as Blow Fill & Seal and sterile unit-dose production positions it as a trusted partner for pharmaceutical clients seeking high-quality, specialized manufacturing solutions, especially for sensitive biologics, vaccines, and sterile products.

Vaccine Development Leadership Unither's active participation in vaccine development initiatives, including partnerships with biotech firms like ONCOVITA and attendance at major vaccine congresses, underscores its capability to support clients in vaccine manufacturing and biologics, opening avenues for collaborations in emerging immunization projects.

Recent Expansion and Investment Recent facility expansions, particularly in France and investments in BFS production lines in China, indicate growth and increased capacity, creating opportunities to engage with the company for new projects, contract manufacturing, or supply chain partnerships in high-demand biologics markets.

Strong Market Presence Generating annual revenues of around €475 million and selling products in over 100 countries, Unither Pharmaceuticals has a broad international market reach, signaling opportunities for global distribution partnerships and expansion collaborations with pharmaceutical and biotech companies seeking a reliable sterile manufacturing partner.